Consensus Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.94 USD -2.03% Intraday chart for Catalyst Pharmaceuticals, Inc. -5.74% -5.18%

Evolution of the average Target Price on Catalyst Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

21b14.ZCWxehNtBnL_v7K0lNEiSWifRtc_lVyz2d1uIsMdyqc.VV3hTUwaTy2F1Obk8ZdVLDjPMpxu-TfJmIcbQJN8pfEiaIYJRRgzPYXH2Q~ff8da1d36f66198a719a890cec3b87a6
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing MT
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23 MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating MT
Oppenheimer Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $30 Price Target MT
Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $24 From $22, Maintains Buy Rating MT
Truist Securities Adjusts Catalyst Pharmaceuticals' Price Target to $22 From $18, Keeps Buy Rating MT
Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $18 From $17, Maintains Buy Rating MT
HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $24 From $18, Keeps Buy Rating MT
Piper Sandler Adjusts Catalyst Pharmaceuticals Price Target to $20 From $18, Maintains Overweight Rating MT
ANALYST RECOMMENDATIONS : Intuit, XPeng, Rio Tinto, Prologis, Charter Communications... Our Logo
Roth Capital Downgrades Catalyst Pharmaceuticals to Neutral From Buy; Price Target is $15.50 MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $18 From $15, Maintains Overweight Rating MT
Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $17 From $12, Maintains Buy Rating MT
HC Wainwright Raises Catalyst Pharmaceuticals' Price Target to $18 From $12, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Catalyst Pharmaceuticals to $16 From $9, Reiterates Overweight Rating MT
History shows stocks can weather rate hike cycle RE
HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $12 From $9, Maintains Buy Rating MT
CATALYST PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Catalyst Pharmaceuticals to $11 From $8, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.94 USD
Average target price
26.86 USD
Spread / Average Target
+68.49%
High Price Target
34 USD
Spread / Highest target
+113.30%
Low Price Target
23 USD
Spread / Lowest Target
+44.29%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Catalyst Pharmaceuticals, Inc.

Citigroup
BofA Securities
Cantor Fitzgerald
Oppenheimer
Truist Securities
HC Wainwright
Piper Sandler
Roth Capital Partners
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Catalyst Pharmaceuticals, Inc. - Nasdaq
  4. Consensus Catalyst Pharmaceuticals, Inc.